Print

Alexion Pharmaceuticals Inc. (ALXN) Release: Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients With aHUS  
11/5/2012 11:00:18 AM

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of two-year data that highlight the long-term benefits of chronic SolirisĀ® (eculizumab) therapy in patients with atypical hemolytic uremic syndrome (aHUS), an ultra-rare genetic disease characterized by thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body. In two pivotal phase 2 studies, which initially enrolled 37 patients, 32 patients entered a long-term extension phase. The data demonstrated that ongoing Soliris treatment for two years was associated with sustained inhibition of complement-mediated TMA, as indicated by a maintained increase in platelet count, and sustained improvement in renal function and TMA event-free status.1,2 The data were presented today at Kidney Week 2012, the annual meeting of the American Society of Nephrology (ASN) in San Diego. Additionally, data presented in a poster session at ASN support early initiation of Soliris therapy regardless of the presence or absence of genetic mutations in patients with aHUS.3
//-->